8 results on '"Deau, Bénédicte"'
Search Results
2. The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)
- Author
-
Deau, Bénédicte, Nicolini, Franck E., Guilhot, Joelle, Huguet, Françoise, Guerci, Agnès, Legros, Laurence, Pautas, Cécile, Berthou, Christian, Guyotat, Denis, Cony-Makhoul, Pascale, Gardembas, Martine, Michallet, Mauricette, Hayette, Sandrine, Cayuela, Jean Michel, Weiss, Isabelle Radford, Réa, Delphine, Castaigne, Sylvie, Mahon, François-Xavier, Guilhot, François, and Rousselot, Philippe
- Subjects
- *
CANCER chemotherapy , *CYTARABINE , *MYELOID leukemia , *DRUG administration , *FOLLOW-up studies (Medicine) , *HEMATOLOGY , *IMATINIB , *COMBINATION drug therapy , *PATIENTS - Abstract
Abstract: Background: The median survival of patients with chronic myelogenous leukemia in myeloid blast crisis (MBC-CML) is poor even for patients treated with tyrosine kinase inhibitors (TKIs). Design and methods: We conducted a dose-escalating study of daunorubicin combined to fixed doses of IM (imatinib mesylate, 600mg/d) and cytarabine (200mg/d for 7 days), followed by hematopoietic stem cell transplantation or maintenance therapy with single-agent IM in patients with MBC-CML at onset or after failure of therapy excluding TKIs. Results: Thirty-six patients were evaluated. Median follow-up is 6.1 years. Daunorubicin was escaladed up to 45mg/m2/d 3 days. Twenty eight patients (77.7%) had hematologic response including 20 patients (55.5%) in complete hematologic response (CHR). Patients who received daunorubicin at 30–45mg/m2/d had higher CHR rates compared to other patients. Median overall survival was 16 months. Overall survival in patients with hematological response was 35.4 months. Better results were observed in patients diagnosed with MBC-CML at onset. Conclusions: The combination of IM with a standard “3+7” regiment was well tolerated and provided a high response rate. More than 55% of the patients achieved CHR and hematopoietic stem cell transplantation (SCT) was feasible in half of the cases. This trial was registered at www.clinicaltrials.gov as # NCT00219765. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
3. The role of radiotherapy as salvage and/or consolidation treatment in relapsed/refractory and high-risk diffuse large B-cell lymphoma.
- Author
-
Grignano, Eric, Laurent, Jérémy, Deau, Bénédicte, Burroni, Barbara, Bouscary, Didier, and Kirova, Youlia M.
- Subjects
- *
RADIOTHERAPY , *B cells , *CANCER chemotherapy , *DOSAGE forms of drugs ,MEDIASTINAL tumors - Abstract
Objective: Many salvage therapies have been proposed for relapsed/refractory (R/R) diffuse large B-cell lymphomas or for consolidation in the case of suboptimal response. Radiotherapy (RT) is one modality of salvage therapy, but its place is currently not well defined. Method: This study reports a retrospective review of patients receiving unplanned radiotherapy for R/R diffuse large B-cell lymphoma (DLBCL) or primary mediastinal B-cell lymphoma (PMBCL), or as consolidation therapy after second-line chemotherapy, treated in our hospital. Results: Fifty-one patients with a median age of 53.5 years [19-89] were selected. The histologic type was DLBCL in 35 cases (68%), PMBCL in 8 cases (16%), and secondary transformed NHL in 8 cases (16%). Median aaIPI was 1 [0-4], and 17 patients (33%) had a high tumor burden (bulky disease). Sixteen patients (31%) were irradiated for a response considered to be insufficient, 18 patients (36%) were refractory, and 17 patients (33%) had relapsed. Patients were irradiated with a median dose of 40 Gy [15-44], 29 (57%) by a conformal 3D technique and 22 (43%) by tomotherapy. With a median follow-up of 36 months [1.0-127.8] after irradiation, 5-year progression-free survival (PFS) and overall survival (OS) were 62% and 72%, respectively. In multivariate analysis, adverse factors associated with PFS and OS in our cohort were age >70 years (HR = 5.06, P = .02) and post-RT relapse (HR = 12.24, P = .002), whereas favorable factors were number of lines of chemotherapy <3 (HR = 0.02, P = .03) and bulky disease (HR = 0.02, P = .009). Conclusion: Due to its low toxicity and ease of use, radiotherapy should therefore remain an available option in patients with R/R DLBCL or as consolidation therapy in patients with high-risk disease, mostly in patients with chemo-sensitive disease or bulky disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
- Author
-
Johnson-Ansah, Hyacinthe, Maneglier, Benjamin, Huguet, Françoise, Legros, Laurence, Escoffre-Barbe, Martine, Gardembas, Martine, Cony-Makhoul, Pascale, Coiteux, Valérie, Sutton, Laurent, Abarah, Wajed, Pouaty, Camille, Pignon, Jean-Michel, Choufi, Bachra, Visanica, Sorin, Deau, Bénédicte, Morisset, Laure, Cayssials, Emilie, Molimard, Mathieu, Bouchet, Stéphane, and Mahon, François-Xavier
- Subjects
- *
NILOTINIB , *CHRONIC myeloid leukemia , *IMATINIB , *DRUG monitoring , *DRUG efficacy - Abstract
The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure. Therapeutic drug monitoring (TDM) is routinely used to maximize a drug's efficacy or tolerance. We decided to conduct a prospective randomized trial (OPTIM-imatinib trial) to assess the value of TDM in patients with chronic phase chronic myelogenous treated with imatinib as first-line therapy (NCT02896842). Eligible patients started imatinib at 400 mg daily, followed by imatinib [C]min assessment. Patients considered underdosed ([C]min < 1000 ng/mL) were randomized in a dose-increase strategy aiming to reach the threshold of 1000 ng/mL (TDM arm) versus standard imatinib management (control arm). Patients with [C]min levels ≥ 1000 ng/mL were treated following current European Leukemia Net recommendations (observational arm). The primary endpoint was the rate of major molecular response (MMR, BCR::ABL1IS ≤ 0.1%) at 12 months. Out of 133 evaluable patients on imatinib 400 mg daily, 86 patients had a [C]min < 1000 ng/mL and were randomized. The TDM strategy resulted in a significant increase in [C]min values with a mean imatinib daily dose of 603 mg daily. Patients included in the TDM arm had a 12-month MMR rate of 67% (95% CI, 51–81) compared to 39% (95% CI, 24–55) for the control arm (p = 0.017). This early advantage persisted over the 3-year study period, in which we considered imatinib cessation as a censoring event. Imatinib TDM was feasible and significantly improved the 12-month MMR rate. This early advantage may be beneficial for patients without easy access to second-line TKIs. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5‐year analysis of the French early access program (EPA).
- Author
-
Manson, Guillaume, Herbaux, Charles, Schiano, Jean‐Marc, Casasnovas, Olivier, Stamatoullas, Aspasia, Deau, Bénédicte, Schmitt, Anna, Regny, Caroline, Bouabdallah, Krimo, Chauchet, Adrien, Ghesquieres, Hervé, Tempescul, Adrian, Dulery, Remy, Nicolas‐Virelizier, Emmanuelle, Delmer, Alain, Borel, Cecile, Dercle, Laurent, Brice, Pauline, and Houot, Roch
- Subjects
- *
HODGKIN'S disease , *DISEASE relapse , *NIVOLUMAB , *HEMATOPOIETIC stem cell transplantation - Abstract
The study included patients with HL relapsing or refractory after three lines of chemotherapy (including brentuximab-vedotin) and autoHSCT, or four lines of chemotherapy if the patient was not eligible for HSCT. To assess whether some patients might be cured with nivolumab alone as systemic treatment, we analysed the 19 patients who achieved a CR and did not receive a consolidation (concomitant radiotherapy was performed in five patients). Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma?. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
6. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation.
- Author
-
Manson, Guillaume, Mear, Jean-Baptiste, Herbaux, Charles, Schiano, Jean-Marc, Casasnovas, Olivier, Stamatoullas, Aspasia, Deau, Bénédicte, Schmitt, Anna, Garnier, Georges, Regny, Caroline, Bouabdallah, Krimo, Moles-Moreau, Marie-Pierre, Ghesquieres, Hervé, Tempescul, Adrian, Dulery, Remy, Nicolas-Virelizier, Emmanuelle, Delmer, Alain, Borel, Cecile, Chauchet, Adrien, and Damotte, Diane
- Subjects
- *
HODGKIN'S disease treatment , *CANCER relapse , *APOPTOSIS , *CANCER patients , *HEMATOPOIETIC stem cell transplantation , *IMMUNOTHERAPY , *LONGITUDINAL method , *SURVIVAL , *TREATMENT effectiveness , *RETROSPECTIVE studies , *DISEASE progression , *DESCRIPTIVE statistics , *EVALUATION , *CANCER treatment - Abstract
Long-term efficacy of anti-PD1 therapy and the need for a consolidation with allogenic haematopoietic stem cell transplantation (allo-HSCT) remain unclear in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). We retrospectively analysed 78 patients with R/R HL treated with nivolumab in the French Early Access Program and compared their outcomes according to subsequent allo-HSCT. After a median follow-up of 34.3 months, the best overall response rate was 65.8%, including 38.2% complete responses (CRs). The median progression-free survival (PFS) was 12.1 months. Patients reaching a CR upon nivolumab had a significantly longer PFS than those reaching a partial response (PR) (median = not reached vs 9.3 months, p < 0.001). In our cohort, 13 patients who responded (i.e. in CR or PR) to nivolumab monotherapy underwent consolidation with allo-HSCT. Among responding patients, none of those who underwent subsequent allo-HSCT (N = 13) relapsed, whereas 62.2% of those who were not consolidated with allo-HSCT (N = 37) relapsed (p < 0.001). There was no difference in overall survival (OS) between the two groups. Five of 6 patients who were not in CR at the time of transplantation (4 PRs and 1 progressive disease) converted into a CR after allo-HSCT. Most patients with R/R HL treated with anti-PD1 monotherapy eventually progressed, notably those who did not achieve a CR. Patients undergoing consolidation with allo-HSCT after anti-PD1 therapy experienced prolonged disease-free survival compared with non-transplanted patients, but this difference did not translate into a benefit in OS. This information should be considered when evaluating the risk/benefit ratio of allo-HSCT after anti-PD1 therapy. • Most patients with relapsed/refractory Hodgkin lymphoma eventually progressed during anti-programmed cell death-1 (anti-PD1) therapy. • In responding patients, the relapse rate was lower in patients consolidated with allogenic haematopoietic stem cell transplantation (allo-HSCT). • Among responders, subsequent allo-HSCT was not associated with a greater overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.
- Author
-
Cottereau, Anne-Ségolène, Versari, Annibale, Loft, Annika, Casasnovas, Olivier, Bellei, Monica, Ricci, Romain, Bardet, Stéphane, Castagnoli, Antonio, Brice, Pauline, Raemaekers, John, Deau, Bénédicte, Fortpied, Catherine, Raveloarivahy, Tiana, Van Zele, Emelie, Chartier, Loic, Vander Borght, Thierry, Federico, Massimo, Hutchings, Martin, Ricardi, Umberto, and Andre, Marc
- Subjects
- *
POSITRON emission tomography , *HODGKIN'S disease , *LYMPHOMAS , *TUMORS , *COMPUTED tomography - Abstract
We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P = .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm3) group (n = 46), respectively, vs 92% and 98% in the low-TMTV group (≤147 cm³). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d'Etude des Lymphomes de l'Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV≤147+DS1-3; 5-year PFS, 95%), low-intermediate (TMTV>147+DS1-3; 5-year PFS, 81.6%), high-intermediate (TMTV≤147+DS4-5; 5-year PFS, 50%), and high (TMTV>147+DS4-5; 5-year PFS, 25%). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
8. Peripheral blood 8 colour flow cytometry monitoring of hairy cell leukaemia allows detection of high-risk patients.
- Author
-
Garnache Ottou, Francine, Chandesris, Marie‐Olivia, Lhermitte, Ludovic, Callens, Céline, Beldjord, Kheira, Garrido, Marlene, Bedin, Anne‐Sophie, Brouzes, Chantal, Villemant, Sarah, Rubio, Marie‐Thérèse, Belanger, Coralie, Suarez, Felipe, Deau, Bénédicte, Lefrère, François, Hermine, Olivier, Asnafi, Vahid, Varet, Bruno, and Macintyre, Elizabeth
- Subjects
- *
HAIRY cell leukemia , *BLOOD diseases , *FLOW cytometry , *B cells , *POLYMERASE chain reaction - Abstract
Although purine analogues have significantly improved the outcome of hairy cell leukaemia ( HCL) patients, 30-40% relapse, illustrating the need for minimal residual disease ( MRD) markers that can aid personalized therapeutic management. Diagnostic samples from 34 HCL patients were used to design an 8-colour flow cytometry (8- FC) tube for blood MRD (B/ RD) analysis (188 samples) which was compared to quantitative IGH polymerase chain reaction (Q- PCR) on 83 samples and to qualitative consensus IGH PCR clonality analysis on 165 samples. Despite heterogeneous HCL phenotypes at diagnosis, discrimination from normal B lymphocytes was possible in all cases using a single 8- FC tube, with a robust sensitivity of detection of 10−4, comparable to Q- PCR at this level, but preferable in terms of informativeness, simplicity and cost. B/ RD assessment of 15 patients achieving haematological complete remission after purine analogues was predictive of a clinically significant relapse risk: with a median follow-up of 95 months; only one of the nine patients with reproducible 8- FC B/ RD levels below 10−4 (B/ RDneg) relapsed, compared to 5/6 in the B/ RDpos group ( P = 0·003). These data demonstrate the clinical interest of a robust 8- FC HCL B/ RD strategy that could become a surrogate biomarker for therapeutic stratification and new drug assessment, which should be evaluated prospectively. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.